In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ceptaris Therapeutics Inc.

Division of Johnson & Johnson
www.ceptaris.com

Latest From Ceptaris Therapeutics Inc.

PatientsLikeMe Pioneers Social Medicine

The social media site, now in its second decade, has over 350,000 users who report on more than 2,500 diseases. It has begun partnering with biopharma companies eager to engage with members and mine patient-reported data on diseases and outcomes.

BioPharmaceutical

Actelion Aims To Expand Opsumit Uses, Build Diversified Pipeline

Actelion says its robust financial performance in 2013, a strong U.S. launch for its new PAH drug Opsumit and a growing pipeline that includes more than 15 preclinical projects has positioned it well for further product diversification in 2014 and beyond.

BioPharmaceutical Switzerland

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

With Valchlor US win, Actelion to move forward on Ceptaris buy

In bringing Valchlor (mechlorethamine) across the FDA finish line on 26 August, Ceptaris held up its end of a merger deal with Swiss drug maker Actelion, which late last month put up $25m to buy the Malvern, Pennsylvania-based specialty pharma, with a pledge to pay another $225m if certain other conditions were met, including having that US drug approval in hand.

Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Yaupon Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Stephen Tullman, Chmn., Pres. & CEO
    Doug Gessl, COO & CFO
    Tim Henkel, MD, PhD, EVP, Head, R&D
    Evan G Dick, PhD, SVP, Bus. Dev.
  • Contact Info
  • Ceptaris Therapeutics Inc.
    Phone: (610) 975-9290
    101 Lindenwood Dr.
    Ste. 400
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register